Výsledky vyhledávání - "Shrina P Thomas"

Reduced-Dose Ibrutinib Is Well Tolerated and Cost Effective for the Treatment of Chronic Lymphocytic Leukemia in Frail Older Adults

Autor: Kathryn M Cappell, Arashpreet Chhina, Maneesh Jain, Shrina P Thomas, Monica Pernia Marin, Elizabeth G Vallejo

Publikováno v: Blood. 138:4967-4967

Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK) that is used for the treatment of multiple hematologic malignancies including chronic lymphocytic leukemia (CLL) with promising outcomes. Its use has been associated with significant side ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::00ce8dc850b745f58dff02f73566263d
https://doi.org/10.1182/blood-2021-154246

Zobrazit plný text záznamu

Reduced-Dose Venetoclax Is Well Tolerated and Cost Effective for the Treatment of Chronic Lymphocytic Leukemia in Frail Older Adults

Autor: Monica Pernia Marin, Malak Alharbi, Arashpreet Chhina, Shrina P Thomas, Maneesh Jain

Publikováno v: Blood. 138:4968-4968

Venetoclax is a potent selective inhibitor of the anti-apoptotic protein B-Cell Lymphoma 2 (BCL2) on tumor cells restoring the process of apoptosis among cancer cells. Venetoclax has been approved by the US Food and Drug administration (FDA) for the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c4021dc45ab47521b57418a48b78d0ef
https://doi.org/10.1182/blood-2021-154487

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání